MMP-3 contributes to nigrostriatal dopaminergic neuronal loss, BBB damage, and neuroinflammation in an MPTP mouse model of Parkinson's disease

Mediators of Inflammation

Volumn 2013, Issue , 2013, Pages

  Chung, Young Cheul ^a,b   Kim, Yoon Seong ^c   Bok, Eugene ^a,c   Yune, Tae Young ^a   Maeng, Sungho ^d   Jin, Byung Kwan ^a  

^a Kyung Hee University Hospital   (South Korea)

^b ROCKEFELLER UNIVERSITY   (United States)

^c UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

^d Kyung Hee University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ALBUMIN; FLUORESCEIN ISOTHIOCYANATE; STROMELYSIN; TYROSINE 3 MONOOXYGENASE; DOPAMINE; MMP3 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CELL COUNT; CELL INFILTRATION; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; MALE; MOTOR PERFORMANCE; MOUSE; NERVOUS SYSTEM INFLAMMATION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; STRIATONIGRAL DEGENERATION; ANIMAL; C57BL MOUSE; DENSITOMETRY; DISEASE MODEL; GENE EXPRESSION REGULATION; INFLAMMATION; METABOLISM; NERVE CELL; PATHOLOGY; PHAGOCYTOSIS; SUBSTANTIA NIGRA; TRANSGENIC MOUSE;

ANIMALS; BLOOD-BRAIN BARRIER; DENSITOMETRY; DISEASE MODELS, ANIMAL; DOPAMINE; GENE EXPRESSION REGULATION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; MALE; MATRIX METALLOPROTEINASE 3; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEURONS; PARKINSON DISEASE; PHAGOCYTOSIS; SUBSTANTIA NIGRA; TYROSINE 3-MONOOXYGENASE;

EID: 84880273031     PISSN: 09629351     EISSN: 14661861     Source Type: Journal    
DOI: 10.1155/2013/370526     Document Type: Article

References (51)

1. Savitt J. M., Dawson V. L., Dawson T. M., Diagnosis and treatment of Parkinson disease: molecules to medicine. Journal of Clinical Investigation 2006 116 7 1744 1754 2-s2.0-33745847479 10.1172/JCI29178
2. + T cells mediate cytotoxicity in neurodegenerative diseases. Journal of Clinical Investigation 2009 119 1 13 15 2-s2.0-61749097003 10.1172/JCI38096
3. Block M. L., Zecca L., Hong J.-S., Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Reviews Neuroscience 2007 8 1 57 69 2-s2.0-33845768784 10.1038/nrn2038
4. Weiss N., Miller F., Cazaubon S., Couraud P.-O., The blood-brain barrier in brain homeostasis and neurological diseases. Biochimica et Biophysica Acta 2009 1788 4 842 857 2-s2.0-63249115678 10.1016/j.bbamem.2008.10.022
5. + lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. Journal of Clinical Investigation 2009 119 1 182 192 2-s2.0-58849107919 10.1172/JCI36470
6. Pisani V., Stefani A., Pierantozzi M., Natoli S., Stanzione P., Franciotta D., Pisani A., Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease. Journal of Neuroinflammation 2012 9 188
7. Faucheux B. A., Bonnet A.-M., Agid Y., Hirsch E. C., Blood vessels change in the mesencephalon of patients with Parkinson's disease. The Lancet 1999 353 9157 981 982 2-s2.0-0033586471
8. Chao Y. X., He B. P., Tay S. S. W., Mesenchymal stem cell transplantation attenuates blood brain barrier damage and neuroinflammation and protects dopaminergic neurons against MPTP toxicity in the substantia nigra in a model of Parkinson's disease. Journal of Neuroimmunology 2009 216 1-2 39 50 2-s2.0-71749083461 10.1016/j.jneuroim.2009.09.003
9. Zhao C., Ling Z., Newman M. B., Bhatia A., Carvey P. M., TNF- α knockout and minocycline treatment attenuates blood-brain barrier leakage in MPTP-treated mice. Neurobiology of Disease 2007 26 1 36 46 2-s2.0-33947323582 10.1016/j.nbd.2006.11.012
10. Kim E.-M., Hwang O., Role of matrix metalloproteinase-3 in neurodegeneration. Journal of Neurochemistry 2011 116 1 22 32 2-s2.0-78650099684 10.1111/j.1471-4159.2010.07082.x
11. van Hove I., Lemmens K., van de Velde S., Verslegers M., Moons L., Matrix metalloproteinase-3 in the central nervous system: a look on the bright side. Journal of Neurochemistry 2012 123 2 203 216
12. Gonthier B., Nasarre C., Roth L., Perraut M., Thomasset N., Roussel G., Aunis D., Bagnard D., Functional interaction between matrix metalloproteinase-3 and semaphorin-3C during cortical axonal growth and guidance. Cerebral Cortex 2007 17 7 1712 1721 2-s2.0-34547665538 10.1093/cercor/bhl082
13. van Hove I., Verslegers M., Buyens T., Delorme N., Lemmens K., Stroobants S., Gantois I., D'Hooge R., Moons L., An aberrant cerebellar development in mice lacking matrix metalloproteinase-3. Molecular Neurobiology 2012 45 1 17 29 2-s2.0-84856748736 10.1007/s12035-011-8215-z
14. Meighan S. E., Meighan P. C., Choudhury P., Davis C. J., Olson M. L., Zornes P. A., Wright J. W., Harding J. W., Effects of extracellular matrix-degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity. Journal of Neurochemistry 2006 96 5 1227 1241 2-s2.0-33645103421 10.1111/j.1471-4159.2005.03565.x
15. Kim Y. S., Kim S. S., Cho J. J., Choi D. H., Hwang O., Shin D. H., Chun H. S., Beal M. F., Joh T. H., Matrix metalloproteinase-3: a novel signaling proteinase from apoptotic neuronal cells that activates microglia. Journal of Neuroscience 2005 25 14 3701 3711 2-s2.0-17044432238 10.1523/JNEUROSCI.4346-04. 2005
16. Gurney K. J., Estrada E. Y., Rosenberg G. A., Blood-brain barrier disruption by stromelysin-1 facilitates neutrophil infiltration in neuroinflammation. Neurobiology of Disease 2006 23 1 87 96 2-s2.0-33745170052 10.1016/j.nbd.2006.02.006
17. Choi D. H., Kim E.-M., Son H. J., Joh T. H., Kim Y. S., Kim D., Flint Beal M., Hwang O., A novel intracellular role of matrix metalloproteinase-3 during apoptosis of dopaminergic cells. Journal of Neurochemistry 2008 106 1 405 415 2-s2.0-45249115717 10.1111/j.1471-4159.2008.05399.x
18. Kim S. T., Kim E.-M., Choi J. H., Son H. J., Ji I. J., Joh T. H., Chung S. J., Hwang O., Matrix metalloproteinase-3 contributes to vulnerability of the nigral dopaminergic neurons. Neurochemistry International 2010 56 1 161 167 2-s2.0-73449128954 10.1016/j.neuint.2009.09.014
19. Sung J. Y., Park S. M., Lee C.-H., Um J. W., Lee H. J., Kim J., Oh Y. J., Lee S.-T., Paik S. R., Chung K. C., Proteolytic cleavage of extracellular secreted α -synuclein via matrix metalloproteinases. Journal of Biological Chemistry 2005 280 26 25216 25224 2-s2.0-21644446495 10.1074/jbc.M503341200
20. Choi D.-H., Kim Y.-J., Kim Y.-G., Joh T. H., Beal M. F., Kim Y.-S., Role of matrix metalloproteinase 3-mediated α -synuclein cleavage in dopaminergic cell death. Journal of Biological Chemistry 2011 286 16 14168 14177 2-s2.0-79954609544 10.1074/jbc.M111.222430
21. Kim S., Moon M., Park S., Exendin-4 protects dopaminergic neurons by inhibition of microglial activation and matrix metalloproteinase-3 expression in an animal model of Parkinson's disease. Journal of Endocrinology 2009 202 3 431 439 2-s2.0-70349334516 10.1677/JOE-09-0132
22. Moon M., Kim H. G., Hwang L., Seo J.-H., Kim S., Hwang S., Kim S., Lee D., Chung H., Oh M. S., Lee K.-T., Park S., Neuroprotective effect of ghrelin in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of parkinson's disease by blocking microglial activation. Neurotoxicity Research 2009 15 4 332 347 2-s2.0-70449527787 10.1007/s12640-009-9037-x
23. Kim Y. S., Choi D. H., Block M. L., Lorenzl S., Yang L., Youn J. K., Sugama S., Byung P. C., Hwang O., Browne S. E., Soo Y. K., Hong J.-S., Beal M. F., Joh T. H., A pivotal role of matrix metalloproteinase-3 activity in dopaminergic neuronal degeneration via microglial activation. The FASEB Journal 2007 21 1 179 187 2-s2.0-33845977715 10.1096/fj.06-5865com
24. Chung Y. C., Bok E., Huh S. H., Park J.-Y., Yoon S.-H., Kim S. R., Kim Y.-S., Maeng S., Park S. H., Jin B. K., Cannabinoid receptor type 1 protects nigrostriatal dopaminergic neurons against MPTP neurotoxicity by inhibiting microglial activation. Journal of Immunology 2011 187 12 6508 6517 2-s2.0-83755178512 10.4049/jimmunol.1102435
25. Chung Y. C., Kim S. R., Jin B. K., Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. Journal of Immunology 2010 185 2 1230 1237 2-s2.0-77955504380 10.4049/jimmunol.1000208
26. Huh S. H., Chung Y. C., Piao Y., Jin M. Y., Son H. J., Yoon N. S., Hong J. Y., Pak Y. K., Kim Y. S., Hong J. K., Hwang O., Jin B. K., Ethyl pyruvate rescues nigrostriatal dopaminergic neurons by regulating glial activation in a mouse model of Parkinson's disease. Journal of Immunology 2011 187 2 960 969 2-s2.0-79960501774 10.4049/jimmunol.1100009
27. Chung Y. C., Kim S. R., Park J.-Y., Chung E. S., Park K. W., Won S. Y., Bok E., Jin M., Park E. S., Yoon S.-H., Ko H. W., Kim Y.-S., Jin B. K., Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 2011 60 6 963 974 2-s2.0-79952449932 10.1016/j.neuropharm.2011.01.043
28. West M. J., Slomianka L., Gundersen H. J. G., Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anatomical Record 1991 231 4 482 497 2-s2.0-0026339976
29. Chagniel L., Robitaille C., Lacharité-Mueller C., Bureau G., Cyr M., Partial dopamine depletion in MPTP-treated mice differentially altered motor skill learning and action control. Behavioural Brain Research 2012 228 1 9 15 2-s2.0-83455181339 10.1016/j.bbr.2011.11.019
30. Kortekaas R., Leenders K. L., van Oostrom J. C. H., Vaalburg W., Bart J., Willemsen A. T. M., Hendrikse N. H., Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo. Annals of Neurology 2005 57 2 176 179 2-s2.0-13144255682 10.1002/ana.20369
31. Chen X., Lan X., Roche I., Liu R., Geiger J. D., Caffeine protects against MPTP-induced blood-brain barrier dysfunction in mouse striatum. Journal of Neurochemistry 2008 107 4 1147 1157 2-s2.0-54349106751 10.1111/j.1471-4159. 2008.05697.x
32. Chung Y. C., Ko H. W., Bok E., Park E. S., Huh S. H., Nam J. H., Jin B. K., The role of neuroinflammation on the pathogenesis of Parkinson's disease. BMB Reports 2010 43 4 225 232 2-s2.0-77953501722
33. Depboylu C., Stricker S., Ghobril J. P., Oertel W. H., Priller J., glinger GU H., Brain-resident microglia predominate over infiltrating myeloid cells in activation, phagocytosis and interaction with T-lymphocytes in the MPTP mouse model of Parkinson disease. Experimental Neurology 2012 238 2 183 191 10.1016/j.expneurol.2012.08.020
34. Kim Y. S., Joh T. H., Microglia, major player in the brain inflammation: their roles in the pathogenesis of Parkinson's disease. Experimental and Molecular Medicine 2006 38 4 333 347 2-s2.0-33748447845
35. Kim E.-M., Shin E.-J., Choi J. H., Son H. J., Park I.-S., Joh T. H., Hwang O., Matrix metalloproteinase-3 is increased and participates in neuronal apoptotic signaling downstream of caspase-12 during endoplasmic reticulum stress. Journal of Biological Chemistry 2010 285 22 16444 16452 2-s2.0-77952764016 10.1074/jbc.M109.093799
36. Cho Y., Son H. J., Kim E.-M., Choi J. H., Kim S. T., Ji I. J., Choi D. H., Joh T. H., Kim Y. S., Hwang O., Doxycycline is neuroprotective against nigral dopaminergic degeneration by a dual mechanism involving MMP-3. Neurotoxicity Research 2009 16 4 361 371 2-s2.0-74949110283 10.1007/s12640-009- 9078-1
37. Son H. J., Lee J. A., Shin N., Choi J. H., Seo J. W., Chi D. Y., Lee C. S., Kim E.-M., Choe H., Hwang O., A novel compound PTIQ protects the nigral dopaminergic neurones in an animal model of Parkinson's disease induced by MPTP. British Journal of Pharmacology 2012 165 7 2213 2227 2-s2.0-84858266820 10.1111/j.1476-5381.2011.01692.x
38. Hirsch E. C., Hunot S., Neuroinflammation in Parkinson's disease: a target for neuroprotection? The Lancet Neurology 2009 8 4 382 397 2-s2.0-62549133546 10.1016/S1474-4422(09)70062-6
39. Tansey M. G., Goldberg M. S., Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention. Neurobiology of Disease 2010 37 3 510 518 2-s2.0-75949087271 10.1016/j.nbd.2009.11.004
40. Abbott N. J., Rönnbäck L., Hansson E., Astrocyte-endothelial interactions at the blood-brain barrier. Nature Reviews Neuroscience 2006 7 1 41 53 2-s2.0-29244463365 10.1038/nrn1824
41. Hawkins B. T., Davis T. P., The blood-brain barrier/neurovascular unit in health and disease. Pharmacological Reviews 2005 57 2 173 185 2-s2.0-22944483792 10.1124/pr.57.2.4
42. Hunot S., Hirsch E. C., Isacson I., Olanow O., Rascol R., Schapira S., Beal B., Jenner J., Neuroinflammatory processes in Parkinson's disease. Annals of Neurology 2003 53 supplement 3 S49 S60 2-s2.0-0037378023 10.1002/ana.10481
43. Zlokovic B. V., The blood-brain barrier in health and chronic neurodegenerative disorders. Neuron 2008 57 2 178 201 2-s2.0-38149090292 10.1016/j.neuron.2008.01.003
44. Carvey P. M., Zhao C. H., Hendey B., Lum H., Trachtenberg J., Desai B. S., Snyder J., Zhu Y. G., Ling Z. D., 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. European Journal of Neuroscience 2005 22 5 1158 1168 2-s2.0-25844442898 10.1111/j.1460-9568.2005.04281.x
45. Rite I., Machado A., Cano J., Venero J. L., Blood-brain barrier disruption induces in vivo degeneration of nigral dopaminergic neurons. Journal of Neurochemistry 2007 101 6 1567 1582 2-s2.0-34249817563 10.1111/j.1471-4159. 2007.04567.x
46. Desai B. S., Monahan A. J., Carvey P. M., Hendey B., Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy. Cell Transplantation 2007 16 3 285 299 2-s2.0-34250623663
47. Monahan A. J., Warren M., Carvey P. M., Neuroinflammation and peripheral immune infiltration in Parkinson's disease: an autoimmune hypothesis. Cell Transplantation 2008 17 4 363 372 2-s2.0-44149103168
48. Choi D.-K., Pennathur S., Perier C., Tieu K., Teismann P., Wu D.-C., Jackson-Lewis V., Vila M., Vonsattel J.-P., Heinecke J. W., Przedborski S., Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice. Journal of Neuroscience 2005 25 28 6594 6600 2-s2.0-22244434468 10.1523/JNEUROSCI.0970-05.2005
49. Nagatsu T., Sawada M., Biochemistry of postmortem brains in Parkinson's disease: historical overview and future prospects. Journal of Neural Transmission 2007 72 113 120 2-s2.0-38449091547 10.1007/978-3-211-73574-9-14
50. Wu D.-C., Teismann P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., Przedborski S., NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2003 100 10 6145 6150 2-s2.0-0037947448 10.1073/pnas.0937239100
51. Wu D. C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.-K., Ischiropoulos H., Przedborski S., Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. Journal of Neuroscience 2002 22 5 1763 1771 2-s2.0-0036522967